<DOC>
	<DOCNO>NCT01809392</DOCNO>
	<brief_summary>Allo - hematopoietic stem cell transplantation currently way cure myelodysplastic syndrome /acute leukemia . The exist experimental result show decitabine 5-azacytidine up-regulated expression tumor Ags leukemic blast vitro expanded number immunomodulatory T regulatory cell animal model . Reasoning decitabine might selectively augment graft versus leukemia effect , investigator use decitabine administration allogeneic stem cell transplantation study immunologic sequela .</brief_summary>
	<brief_title>Decitabine Augments Post Allogeneic Stem Cell Transplantation Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologically confirm AML complete partial remission MDS use WHO classification undergo alloHSCT High resolution type HLAmatched relate unrelated donor . Donors may mismatch single antigen HLAA , B DR locus plus possible single antigen mismatch HLAC accord institution guideline . Twoantigen mismatch single locus allow . Age ≥ 18 creatinine &lt; 1.5 time institutional ULN creatinine clearance ( calculate Cockroft Gault method ) ≥ 30 mL/min bilirubin &lt; 1.5 time institutional ULN AST , ALT alkaline phosphatase &lt; 2.5 time institutional ULN . History previous alloHSCT prior current alloHSCT . Persistent AML MDS alloHSCT . Positive serology HIV . Pregnancy nursing . Other cancer less equal 2 year prior study entry except : basal cell carcinoma skin , squamous cell carcinoma skin , carcinoma situ cervix , carcinoma situ breast , prostate cancer stage T1a T1b . Uncontrolled active infection require intravenous antibiotic . Clinically significant systemic illness ( e.g . serious active infection significant cardiac , pulmonary , hepatic organ dysfunction ) , , judgment Principal Associate Investigator would compromise patient 's ability tolerate protocol therapy . Known suspected hypersensitivity decitabine . Patients may receive investigational agent . General specific change patient 's condition render patient unacceptable treatment judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Decitabine</keyword>
	<keyword>hematopoietic stem cell transplant</keyword>
	<keyword>Wilms ' tumor 1</keyword>
	<keyword>cytolytic T lymphocyte</keyword>
	<keyword>Regulatory T cell</keyword>
</DOC>